Lymphoblastic lymphoma

Abstract

Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are largely overlapping entities based on morphology, immunophenotype, and molecular aberrations. Arbitrary distinctions are made between these entities by the extent of marrow involvement. Juxtaposition of genes encoding oncogenic transcription factor to T-cell receptor genes, activating Notch mutations, and loss of tumor suppressors are common events in T-LBL. Adoption of ALL-like therapy and pediatric regimens has improved outcome in LBL. Treatments targeting Notch, mTOR/Akt pathways, etc. and newer nucleoside analogs are expected to improve outcome in LBL.